| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Mereo BioPharma Group plc | Alvelestat - (ASTRAEUS) | Severe alpha-1 antitrypsin deficiency (AATD) | Phase 2 | Data Released | Oral | Genetic Disorder |
| Merrimack Pharmaceuticals Inc. | MM-121 SHERLOC | Cancer - Heregulin Positive Non-Small Cell Lung Cancer | Phase 2 | intravenous | Oncology | |
| Merrimack Pharmaceuticals Inc. | MM-302 HERMIONE | Cancer - HER2-positive locally advanced or metastatic breast cancer | Phase 2 | Intravenous | Oncology | |
| Merrimack Pharmaceuticals Inc. | MM-141 - CARRIE | Cancer - front line pancreatic cancer | Phase 2 | intravenous | Oncology | |
| Merrimack Pharmaceuticals Inc. | MM-121 (SHERBOC) | HER2 negative metastatic breast cancer | Phase 2 | Intravenous | Oncology | |
| Merrimack Pharmaceuticals Inc. | MM-121 (SHERBOC) | HER2 negative metastatic breast cancer | Phase 2 | Intravenous | Oncology | |
| Merus N.V. | MCLA-129 - (ZENO) | Solid Tumors, MET ex14 NSCLC | Phase 3 | Data Released | Intravenous | Oncology |
| Merus N.V. | MCLA-129 - (ZENO) | Solid Tumors, MET ex14 NSCLC | Phase 3 | Data Released | Intravenous | Oncology |